10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
08:03Advanced Self-Healing Asphalt Reinforced by Graphene Structures: An Atomistic Insight
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Molecular Structure and Acidity
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 19, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Gavin W Collie1, Cheryl M Koh2, Daniel J O'Neill1
1Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K.
Understanding the cMET D1228V mutation is crucial for cancer treatment. This study reveals how this mutation affects small molecule inhibitor binding, guiding future drug design for resistant cancers.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: